<DOC>
	<DOCNO>NCT00748163</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel albumin-stabilized nanoparticle formulation , work different way stop growth tumor cell , either kill cell stop dividing . Sunitinib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Giving paclitaxel albumin-stabilized nanoparticle formulation together sunitinib may kill tumor cell . PURPOSE : This phase II trial study well give paclitaxel albumin-stabilized nanoparticle formulation together sunitinib work first-line therapy treat patient stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Paclitaxel Albumin-Stabilized Nanoparticle Formulation Sunitinib First-Line Therapy Treating Patients With Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine tumor response rate patient stage IV non-small cell lung cancer treat paclitaxel albumin-stabilized nanoparticle formulation sunitinib malate first-line therapy . Secondary - To determine time objective tumor response duration response respond patient . - To determine time treatment failure overall survival patient . - To characterize toxicity regimen patient . OUTLINE : Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV 30 minute day 1 , 8 , 15 . Patients also receive oral sunitinib malate daily day 1-28 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . After completion study therapy , patient follow every 8 week disease progression every 3 month 1 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Stage IV disease At least 1 measurable lesion define modified RECIST criterion No symptomatic untreated brain metastasis Prior brain metastasis allow provide CNS disease treat consider stable patient recover acute toxic effect treatment prior study entry PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status 01 WBC ≥ 3.0 x 10^9/L ANC ≥ 1.5 x 10^9/L Platelet count ≥ 100 x 10^9/L Bilirubin ≤ 1.5 mg/dL AST ALT ≤ 2.5 time upper limit normal ( ULN ) ( ≤ 5 time ULN liver tumor involvement ) Creatinine ≤ 1.5 mg/dL LVEF ≥ 40 % MUGA Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment Exclusion criterion : Congestive heart failure , myocardial infarction , coronary artery bypass graft within past 12 month Ongoing severe unstable angina Unstable arrhythmia require medication Sensory neuropathy ≥ grade 2 ( accord NCI CTCAE v3.0 ) Known hypersensitivity agent use study Serious medical psychiatric illness , opinion enrol investigator , likely interfere study participation PRIOR CONCURRENT THERAPY : No prior systemic therapy NSCLC More 4 week since prior major surgery More 7 day since prior concurrent potent CYP3A4 inhibitor , include follow : Ketoconazole Itraconazole Clarithromycin Erythromycin Diltiazem Verapamil Delavirdine Indinavir Saquinavir Ritonavir Atazanavir Nelfinavir More 12 day since prior concurrent potent CYP3A4 inducer , include follow : Rifampin Rifabutin Carbamazepine Phenobarbital Phenytoin St. John 's wort Efavirenz Tipranavir No concurrent treatment drug proarrhythmic potential , include follow : Terfenadine Quinidine Procainamide Disopyramide Sotalol Probucol Bepridil Haloperidol Risperidone Indapamide Flecainide No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>